Compare Quest Diagnostics Inc (DGX) vs abrdn Physical Palladium Shares ETF (PALL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs abrdn Physical Palladium Shares ETF — how do they compare? Quest Diagnostics Inc trades at $230.44 (market cap $25.48B), while abrdn Physical Palladium Shares ETF trades at $20.83 (market cap $586.03M). The key difference: Quest Diagnostics Inc is far larger — about 43.5× abrdn Physical Palladium Shares ETF's market cap, and Quest Diagnostics Inc pays a 1.49% dividend while abrdn Physical Palladium Shares ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Quest Diagnostics Inc for 56 Days and abrdn Physical Palladium Shares ETF for 33 Days on average.
| DGX | PALL | |
|---|---|---|
Market Cap | $25.48B | $586.03M |
Volume | 941,866 | 1,257,028 |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $247.45 | $37.18 |
52-Week Low | $173.49 | $20.30 |
Typical Hold Time | 56 Days | 33 Days |
Enterprise Value | $31.23B | — |
Dividend Yield | 1.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $227.00, down 0.64% with a bearish technical signal. The company shows strong fundamentals with three consecutive quarterly earnings beats and revenue growth from $9.9B in 2024 to $11.0B in 2025. Recent developments include positive clinical study results and a new Apple Health integration, though Medicare reimbursement cuts pose headwinds. The stock trades near support at $226 with oversold RSI readings suggesting potential for near-term bounce.
DGX presents a mixed outlook with solid execution offset by regulatory risks. The 10% upside to consensus price target of $250 offers opportunity, but Medicare payment reductions and rising debt levels require monitoring. Recent earnings momentum and strategic partnerships support growth, making DGX suitable for investors comfortable with healthcare sector volatility.
PALL (Aberdeen Physical Palladium Shares ETF) trades at $20.30, down 4.47% with bearish technical signals from moving averages but bullish RSI readings. The ETF tracks palladium prices, which have declined 47% from January 2026 highs. Recent news highlights palladium's underperformance versus gold and silver, with some analysts viewing current levels as a buying opportunity given supply risks and industrial demand.
PALL presents a contrarian opportunity as palladium approaches technical support levels, though the metal faces headwinds from automotive sector volatility. The ETF's value depends entirely on palladium price movements rather than company fundamentals, creating pure commodity exposure with significant price volatility risk.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About abrdn Physical Palladium Shares ETF
PALL is a physically-backed ETF that tracks the spot price of palladium. It holds physical bullion in secure vaults, offering a liquid way to invest in this precious metal primarily used in automotive catalytic converters and electronics.
Read more on PALL →
